Posts in: investor

Transcript: EXOZ investor update - 4Q + full year 2025 @ March 31, 2026
investor
Transcript: EXOZ investor update - 4Q + full year 2025 @ March 31, 2026April 1, 2026
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
press releaseinvestor
eXoZymes Provides Fourth Quarter and Full Year 2025 UpdateMarch 31, 2026
Q4 + 2025 investor call
investor
Sign up: EXOZ investor update - 4Q + full year 2025 @ March 31, 2026March 25, 2026
eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output
investornutraceuticalsmedicine
EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade outputMarch 18, 2026
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026
investorpress clippingsvideo
The Big Skinny: Lou Basenese states that eXoZymes is the BASF of 2026February 16, 2026
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creation
press releaseinvestor
With refreshed brand eXoZymes sharpens pharmaceutical focus to drive platform leverage and long-term value creationFebruary 10, 2026
Nasdaq's 'Amplify Spotlight'
heltzeninvestorpress clippingsvideo
Nasdaq: Michael B. Spector interviews CEO HeltzenFebruary 5, 2026
yahoo! finance
investorpress clippings
yahoo! finance: eXoZymes demonstrates end-to-end biomanufacturability of NCT, from reaction to high-purity isolated productJanuary 30, 2026
Pharma-grade NCT ready for partner testing
press releaseinvestornutraceuticalsscience
eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot runJanuary 29, 2026
Capital Markets Advisor, Sanjeev Srivastava, interviewed by Maxine Hoover
investorpress clippingsvideo
Beryl Elites: Interview with Capital Markets Advisor, Sanjeev SrivastavaJanuary 8, 2026
Previous page
Page 1 of 8
Next page